SEC Form 4 · accession 0000899243-15-010382
CytoDyn Inc. · CYDY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony Caracciolo
Director
Period of report
Dec 21, 2015
Accepted (ET)
Dec 23, 2015 · 7:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175680
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F1,F2 | $2.90 | Dec 21, 2015 | D | 11,543 | D | — | May 21, 2017 | Common Stock | 11,543 | 0 | D |
| Stock Options (right to buy)F1,F2 | $2.90 | Dec 21, 2015 | A | 11,543 | A | — | May 21, 2022 | Common Stock | 11,543 | 11,543 | D |
| Stock Options (right to buy)F1,F2 | $1.55 | Dec 21, 2015 | D | 25,000 | D | — | Jun 1, 2017 | Common Stock | 25,000 | 0 | D |
| Stock Options (right to buy)F1,F2 | $1.55 | Dec 21, 2015 | A | 25,000 | A | — | Jun 1, 2022 | Common Stock | 25,000 | 25,000 | D |
| Stock Options (right to buy)F1,F3 | $0.975 | Dec 21, 2015 | D | 50,000 | D | — | Jun 1, 2020 | Common Stock | 50,000 | 0 | D |
| Stock Options (right to buy)F1,F3 | $0.975 | Dec 21, 2015 | A | 50,000 | A | — | Jun 1, 2025 | Common Stock | 50,000 | 50,000 | D |
| Stock Options (right to buy)F1,F2 | $0.97 | Dec 21, 2015 | D | 250,000 | D | — | Jun 11, 2020 | Common Stock | 250,000 | 0 | D |
| Stock Options (right to buy)F1,F2 | $0.97 | Dec 21, 2015 | A | 250,000 | A | — | Jun 11, 2025 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions.
- F2Such options were fully vested and exercisable as of the date of the reported transactions.
- F3Such options were originally granted on June 1, 2015 and provide for vesting in four equal quarterly installments commencing on September 1, 2015.